LU87009A1 - Compositions pharmaceutiques a liberation prolongee - Google Patents

Compositions pharmaceutiques a liberation prolongee Download PDF

Info

Publication number: LU87009A1
Authority: LU; Luxembourg
Prior art keywords: pharmaceutical composition; composition according; acetylsalicylic acid; hydroxypropyl; acid
Prior art date: 1986-10-09

Application number

LU87009A

Other languages

English (en)

French (fr)

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-10-09

Filing date

1987-10-06

Publication date

1988-05-03

1987-10-06 Application filed by Sandoz Sa filed Critical Sandoz Sa

1988-05-03 Publication of LU87009A1 publication Critical patent/LU87009A1/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 45
239000012730 sustained-release form Substances 0.000 title claims description 8
238000013268 sustained release Methods 0.000 title claims description 6
229960001138 acetylsalicylic acid Drugs 0.000 claims description 45
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 43
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 40
239000000203 mixture Substances 0.000 claims description 27
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 20
229960004889 salicylic acid Drugs 0.000 claims description 20
239000013543 active substance Substances 0.000 claims description 17
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 16
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 16
239000008108 microcrystalline cellulose Substances 0.000 claims description 16
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 16
229940016286 microcrystalline cellulose Drugs 0.000 claims description 16
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 15
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 15
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 15
229920000881 Modified starch Polymers 0.000 claims description 13
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
-1 hydroxypropyl groups Chemical group 0.000 claims description 5
238000004090 dissolution Methods 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
238000007906 compression Methods 0.000 claims description 2
230000006835 compression Effects 0.000 claims description 2
238000006116 polymerization reaction Methods 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims 1
239000001923 methylcellulose Substances 0.000 claims 1
229960002900 methylcellulose Drugs 0.000 claims 1
238000009472 formulation Methods 0.000 description 15
229960001860 salicylate Drugs 0.000 description 11
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
210000002381 plasma Anatomy 0.000 description 9
238000012360 testing method Methods 0.000 description 9
238000000034 method Methods 0.000 description 7
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 6
230000008030 elimination Effects 0.000 description 6
238000003379 elimination reaction Methods 0.000 description 6
210000002700 urine Anatomy 0.000 description 6
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
235000021355 Stearic acid Nutrition 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
239000002245 particle Substances 0.000 description 4
238000010972 statistical evaluation Methods 0.000 description 4
239000008117 stearic acid Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
229920000945 Amylopectin Polymers 0.000 description 3
229920000856 Amylose Polymers 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000008119 colloidal silica Substances 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000126 substance Substances 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
230000001754 anti-pyretic effect Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000001514 detection method Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
DAUAQNGYDSHRET-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC DAUAQNGYDSHRET-UHFFFAOYSA-N 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
241000052343 Dares Species 0.000 description 1
206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
229920003095 Methocel™ K15M Polymers 0.000 description 1
206010029240 Neuritis Diseases 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
208000008765 Sciatica Diseases 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
GPVDHNVGGIAOQT-UHFFFAOYSA-N Veratric acid Natural products COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003831 antifriction material Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
238000013475 authorization Methods 0.000 description 1
238000009534 blood test Methods 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
QPADNTZLUBYNEN-UHFFFAOYSA-N etallobarbital Chemical compound C=CCC1(CC)C(=O)NC(=O)NC1=O QPADNTZLUBYNEN-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
230000010355 oscillation Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000029305 taxis Effects 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

LU87009A 1986-10-09 1987-10-06 Compositions pharmaceutiques a liberation prolongee LU87009A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8624213		1986-10-09
GB868624213A GB8624213D0 (en)	1986-10-09	1986-10-09	Sustained release pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
LU87009A1 true LU87009A1 (fr)	1988-05-03

Family

ID=10605478

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU87009A LU87009A1 (fr)	1986-10-09	1987-10-06	Compositions pharmaceutiques a liberation prolongee

Country Status (24)

Country	Link
JP (1)	JPS63101334A (es)
KR (1)	KR880004801A (es)
AU (1)	AU7942087A (es)
BE (1)	BE1000732A5 (es)
CA (1)	CA1332809C (es)
CH (1)	CH675831A5 (es)
DE (1)	DE3733540A1 (es)
DK (1)	DK527487A (es)
ES (1)	ES2014518A6 (es)
FI (1)	FI874414L (es)
FR (1)	FR2604902B1 (es)
GB (2)	GB8624213D0 (es)
GR (1)	GR871550B (es)
HU (1)	HU201875B (es)
IL (1)	IL84104A0 (es)
IT (1)	IT1221493B (es)
LU (1)	LU87009A1 (es)
NL (1)	NL8702294A (es)
NO (1)	NO874200L (es)
NZ (1)	NZ222083A (es)
PH (1)	PH24227A (es)
PT (1)	PT85880B (es)
SE (1)	SE8703889L (es)
ZA (1)	ZA877617B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5948437A (en) *	1996-05-23	1999-09-07	Zeneca Limited	Pharmaceutical compositions using thiazepine
US5895663A (en) *	1997-07-31	1999-04-20	L. Perrigo Company	Pseudoephedrine hydrochloride extended-release tablets
PL198797B1 (pl) *	1999-03-31	2008-07-31	Janssen Pharmaceutica Nv	Zastosowanie wstępnie żelowanej skrobi
US6242003B1 (en)	2000-04-13	2001-06-05	Novartis Ag	Organic compounds
US20060127474A1 (en)	2001-04-11	2006-06-15	Oskar Kalb	Pharmaceutical compositions comprising fluvastatin
SE0102888D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
SE0102886D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
SE0102887D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
TWI338583B (en)	2004-05-20	2011-03-11	Otsuka Pharma Co Ltd	Solid pharmaceutical formulation
ES2330227T3 (es) *	2004-09-09	2009-12-07	Psicofarma, S.A. De C.V.	Composicion farmaceutica de liberacion prolongada de hidralazina y su uso como apoyo para el tratamiento de cancer.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE795766A (fr) *	1972-02-22	1973-08-22	Lilly Co Eli	Particules de napsylate de propoxyphene retard et procede de fabrication de ces particules
US4389393A (en) *	1982-03-26	1983-06-21	Forest Laboratories, Inc.	Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4520009A (en) *	1983-11-28	1985-05-28	Verex Laboratories, Inc.	Sustained released aspirin formulation
DE3346571A1 (de) *	1983-12-23	1985-07-04	Bayer Ag, 5090 Leverkusen	Oral retardierte acetylsalicylsaeureformulierungen
WO1985004100A1 (en) *	1984-03-21	1985-09-26	American Home Products Corporation	Sustained release pharmaceutical capsules

1986
- 1986-10-09 GB GB868624213A patent/GB8624213D0/en active Pending
1987
- 1987-09-25 NL NL8702294A patent/NL8702294A/nl not_active Application Discontinuation
- 1987-09-25 HU HU874311A patent/HU201875B/hu not_active IP Right Cessation
- 1987-10-02 CH CH3838/87A patent/CH675831A5/de not_active IP Right Cessation
- 1987-10-02 FR FR878713759A patent/FR2604902B1/fr not_active Expired - Lifetime
- 1987-10-02 BE BE8701131A patent/BE1000732A5/fr not_active IP Right Cessation
- 1987-10-03 DE DE19873733540 patent/DE3733540A1/de not_active Withdrawn
- 1987-10-06 IL IL84104A patent/IL84104A0/xx unknown
- 1987-10-06 LU LU87009A patent/LU87009A1/fr unknown
- 1987-10-06 KR KR870011168A patent/KR880004801A/ko not_active Withdrawn
- 1987-10-07 GR GR871550A patent/GR871550B/el unknown
- 1987-10-07 GB GB8723515A patent/GB2195893B/en not_active Expired - Lifetime
- 1987-10-07 NO NO874200A patent/NO874200L/no unknown
- 1987-10-07 AU AU79420/87A patent/AU7942087A/en not_active Abandoned
- 1987-10-07 FI FI874414A patent/FI874414L/fi not_active IP Right Cessation
- 1987-10-07 PT PT85880A patent/PT85880B/pt not_active IP Right Cessation
- 1987-10-07 NZ NZ222083A patent/NZ222083A/en unknown
- 1987-10-08 CA CA000548872A patent/CA1332809C/en not_active Expired - Lifetime
- 1987-10-08 PH PH35906A patent/PH24227A/en unknown
- 1987-10-08 JP JP62256149A patent/JPS63101334A/ja active Pending
- 1987-10-08 ES ES8702873A patent/ES2014518A6/es not_active Expired - Lifetime
- 1987-10-08 IT IT48469/87A patent/IT1221493B/it active
- 1987-10-08 SE SE8703889A patent/SE8703889L/ not_active Application Discontinuation
- 1987-10-08 DK DK527487A patent/DK527487A/da not_active Application Discontinuation
- 1987-10-09 ZA ZA877617A patent/ZA877617B/xx unknown

Also Published As

Publication number	Publication date
FI874414A7 (fi)	1988-04-10
HU201875B (en)	1991-01-28
IT1221493B (it)	1990-07-06
SE8703889L (sv)	1988-04-10
FR2604902B1 (fr)	1991-04-26
HUT52958A (en)	1990-09-28
ZA877617B (en)	1989-05-30
NZ222083A (en)	1991-05-28
NO874200D0 (no)	1987-10-07
KR880004801A (ko)	1988-06-27
GB8624213D0 (en)	1986-11-12
PH24227A (en)	1990-05-04
FI874414A0 (fi)	1987-10-07
GB8723515D0 (en)	1987-11-11
DK527487A (da)	1988-04-10
CH675831A5 (es)	1990-11-15
AU7942087A (en)	1988-04-14
FI874414L (fi)	1988-04-10
GB2195893A (en)	1988-04-20
IL84104A0 (en)	1988-03-31
ES2014518A6 (es)	1990-07-16
FR2604902A1 (fr)	1988-04-15
GB2195893B (en)	1991-05-08
CA1332809C (en)	1994-11-01
DE3733540A1 (de)	1988-04-14
NO874200L (no)	1988-04-11
GR871550B (en)	1988-02-15
NL8702294A (nl)	1988-05-02
IT8748469A0 (it)	1987-10-08
BE1000732A5 (fr)	1989-03-21
PT85880A (en)	1987-11-01
DK527487D0 (da)	1987-10-08
JPS63101334A (ja)	1988-05-06
PT85880B (pt)	1990-07-31
SE8703889D0 (sv)	1987-10-08

Publication	Publication Date	Title
JP5658172B2 (ja)	2015-01-21	アムロジピン及びロサルタンを含む固形薬剤学的組成物及びその製造方法
CA2629670C (fr)	2012-04-17	Forme galenique secable permettant une liberation modifiee du principe actif
EP2605757B1 (fr)	2015-07-01	Formulations a base de nalbuphine et leurs utilisations
CN105792813B (zh)	2019-11-19	一种含有氨氯地平、氯沙坦和罗苏伐他汀的药物组合制剂
EA019614B1 (ru)	2014-05-30	Усовершенствованная фармацевтическая композиция, содержащая антагонист дигидропиридинкальциевого канала, и способ ее получения
NO333936B1 (no)	2013-10-28	Oralt farmasøytisk preparat som inneholder minst to separate formuleringer
TW201111368A (en)	2011-04-01	Solid pharmaceutical fixed dose compositions comprising irbesartan, and amlodipine, their preparation and their therapeutic application
BE1000661A4 (fr)	1989-03-07	Nouvelles compositions pharmaceutiques a base de ketotifene.
CA2287800C (fr)	2012-02-21	Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellulose a titre d'agents desintegrants, et procede d'obtention
BE1000732A5 (fr)	1989-03-21	Compositions pharmaceutiques a liberation prolongee.
CN101410103B (zh)	2013-04-10	固体药物制剂
TWI714560B (zh)	2021-01-01	包含安洛待平（ａｍｌｏｄｉｐｉｎｅ）、洛沙坦（ｌｏｓａｒｔａｎ）及氯薩利酮（ｃｈｌｏｒｔｈａｌｉｄｏｎｅ）的醫藥複合調配物
EP0983065A1 (fr)	2000-03-08	Composition pharmaceutique a residence gastrique
CN107018650B (zh)	2021-02-02	包含氨氯地平和氯沙坦的固体药物组合物
EP1781295A1 (fr)	2007-05-09	Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
CA2853117A1 (en)	2013-05-02	Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
EP1465607B1 (fr)	2007-03-21	Compositions pharmaceutiques a liberation modifiee
JP4945043B2 (ja)	2012-06-06	モルシドミンの放出時間延長を伴う経口投与用新規生薬製剤
EP3727344A1 (en)	2020-10-28	Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin
FR2560047A1 (fr)	1985-08-30	Compositions de bromocriptine
CA2642414A1 (en)	2007-08-23	Rapid release irbesartan-containing pharmaceutical composition
LU86615A1 (fr)	1987-04-02	Nouvelle formulation a liberation prolongee
CA2611125A1 (fr)	2007-01-11	Formulation a liberation prolongee de principes actifs de medicaments
Jagdale et al.	2010	Superdisintegrant selection for tramadol dispersible tablets